» Articles » PMID: 33458405

Comparison of Time Curves from Dynamic F-fluciclovine Positron Emission Tomography and Dynamic Contrast-enhanced Magnetic Resonance Imaging for Primary Prostate Carcinomas

Overview
Specialty Oncology
Date 2021 Jan 18
PMID 33458405
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Multimodal imaging is increasingly included in the assessment of prostate cancer patients, and there is a need to study whether different techniques provide similar or complementary information. In the initial perfusion phase contrast agents and radioactive labelled tracers act as blood-pool agents and may show similar characteristics. The purpose of the current work was to compare time-activity- and time-concentration-curves (TCs) of dynamic F-fluciclovine (F-anti-1-amino-2-[F]-fluorocyclobutane-1-carboxylic acid, FACBC) positron emission tomography (PET) and dynamic contrast-enhanced magnetic resonance imaging (DCE MRI).

Materials And Methods: Dynamic FACBC PET and DCE MRI were performed on 22 patients with intermediate or high-risk prostate cancer within 23 days prior to robot-assisted laparoscopic prostatectomy. Index tumour was delineated in the images using whole mount tissue sections as reference standard. Tumour TCs from PET and MRI were compared visually and quantitatively by calculating correlation coefficients between the curves at different time points after injection.

Results: For the first minute post injection, the mean correlation coefficient between the TCs from PET and MRI was 0.92 (range; 0.75-0.99). After the first minute, MRI showed washout while PET showed plateau kinetics.

Conclusion: Dynamic FACBC and DCE MRI showed similar wash-in time curve characteristics. At later time points, FACBC plateaued whereas MR contrast medium washed out. In DCE MRI, the usefulness of wash-in information is well documented. Whether wash-in information from dynamic FACBC can provide added value remains to be documented.

Citing Articles

Blanching Defects at the Pressure Points: Observations from Dynamic Total-Body PET/CT Studies.

Abdelhafez Y, Mcbride K, Leung E, Hunt H, Spencer B, Lopez J J Nucl Med Technol. 2022; .

PMID: 35440473 PMC: 9745988. DOI: 10.2967/jnmt.122.263905.


Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.

Hole K, Tulipan A, Reijnen J, Hernes E, Vlatkovic L, Lie A Am J Nucl Med Mol Imaging. 2021; 11(5):387-394.

PMID: 34754609 PMC: 8569330.


Imaging science and development in modern high-precision radiotherapy.

Thorwarth D, Muren L Phys Imaging Radiat Oncol. 2021; 12:63-66.

PMID: 33458297 PMC: 7807660. DOI: 10.1016/j.phro.2019.11.008.


Imaging for radiation treatment planning and monitoring in prostate Cancer: Precision, personalization, individualization of therapy.

Grosu A, van der Heide U Phys Imaging Radiat Oncol. 2021; 11:61-62.

PMID: 33458279 PMC: 7807567. DOI: 10.1016/j.phro.2019.09.001.

References
1.
Canet E, Casali C, Desenfant A, An M, Corot C, Obadia J . Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med. 2000; 43(3):403-9. DOI: 10.1002/(sici)1522-2594(200003)43:3<403::aid-mrm12>3.0.co;2-6. View

2.
Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M . Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011; 52(5):822-9. DOI: 10.2967/jnumed.110.086074. View

3.
Sorensen J, Owenius R, Lax M, Johansson S . Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2012; 40(3):394-402. DOI: 10.1007/s00259-012-2291-9. View

4.
Barentsz J, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G . ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4):746-57. PMC: 3297750. DOI: 10.1007/s00330-011-2377-y. View

5.
Epstein J . An update of the Gleason grading system. J Urol. 2009; 183(2):433-40. DOI: 10.1016/j.juro.2009.10.046. View